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CHAPTER - I 
GENERAL INTRODUCTION 
1 
Analytical Chemistry is concerned with the 
theory and practice of methods used to determine the compo-
sition of matter. The Science of Analysis can be divided 
into areas called qualitative analysis and quantitative 
analysis. It is concerned with what elements or compounds 
are present in the sample. Quantitative anlaysis is 
concerned with the determination of how much of particular 
substance is present in the sample. The substance 
determined, often referred to as the desired constituents 
or analyte, may constitute small or large part of the 
sample analyzed. A complete analysis actually consist of 
five main steps: (1) sampling, that is , selection of 
a representative sample of the material to be analyzed; (2) 
dissolution of the sample; (3) conversion of anlayte into 
a form suitable for measurments; (U) measurement; and 
(5) calculation and interpretation of the measurement. 
The importance of Analytical Chemistry can be 
illustrated by considering its impact on clinical 
anlaysis, in pharmaceutical research and quality control, 
and in environmental anlaysis. 
In the past, medical profession used clinical 
results qualitatively and many of their diagnoses were 
based on symptoms and/or X-ray examination. Currently, 
over one billion laboratory tests are performed in 
clinical laboratories per year. The major portion of 
these test deal with blood and urine samples and 
include the determination of glucos e, urea nitrogen, 
protein nitrogen, soduim potassium, calcuim HCo3/H2C03, 
uric acid and pH. 
In the pharmaceutical industry the quality of 
the manufactured drugs in tablet, solution and emulsion 
form must be carefully controlled. Slight changes in 
composition or in the purity of drug itself can affect 
the therapeutic values. In other pharmaceutical studies, 
it is necessary. to establish the properties and 
therapeutic value of a drug before it is approved 
and made available to the public. Establishment of the 
permissible level of dosage of a drug requires the 
determination of its decomposition product, its toxicity, 
and its metabolite products at various stages. 
It is an important task for the practicing 
analytical chemist to choose an analytical method 
which provides the best solution to the problem. 
Methods of quantitative testing and quality control of 
pharmaceuticals are controlled by FDA, Fedral Drug 
Administration. 
Pharmaceutical analysis, today, is on the 
frontiers of Analytical Chemistry. Analysis in both 
bulk and dosage forms is important. The matrix in 
many cases may be extremely complex and therefore. 
detection, determination and some form of separation is 
usually required• Usually methods should be comparable 
to or improvements over methods published from 
standard (B.P., U.S.P., I.P.) pharmacopeia laboratory. 
All the drugs in their nature are divided 
into inorganic and organic. Both can be prepared from 
natural sources, or artificially i.e. synthetically. 
The enormous number of drugs used in medicine can be 
classified into two ways. 
1, PHARMACOLOGICAL CLASSIFICATION ; In this section, 
drugs are divided on the bases of their action on an 
organis m (the heart, brain, lymphatic system, 
stomach, intestine etc.) Accordingly, drugs are 
divided into such groups as narcotic s,, soporifics, 
analgesi'cs diuertics and local anaesthetics. 
2. CHEMICAL CLASSIFICATION : Here, the drugs are divided 
according to their chemical structure and properties 
regardless of their pharmacological action. It is 
beyond the scope of this work to discuss all the 
types of drugs, however, few important class of 
compound used as drugs in medicine are discussed 
below. 
ALKALOIDS : Alkaloids are substances mostly of plants 
and rarely of animal origin. In medicine alkaloids 
are sucess fully used as drugs in the treatment of 
cardiovascular, nervous, alimentary tract and many 
other diseases (1) They are organic substances of basic 
nature because their molecule always contain nitrogen. 
The alkaloids are chiefly tertiary amines, and only 
some of them are secondary amines or derivatives of 
tetrasubstituted ammonium bases. Such class of durgs 
can be grouped into the following heads. 
(i) pyridine and piperidine derivatives (labeline 
and its companions). 
(ii) tropane derivatives (atropine, hyoscyamines, 
cocaine etc) 
(iii) guinoline derivatives (guinoHnet guidine etc), 
(ly) isoguinoline derivatives (opium, alkaloids). 
(v) indole derivatives (physostigmine, reserpine etc) 
(vi) imidazol derivatives (pilocarbine, omeperazole). 
(vii) purine derivatives (caffeine, theobromine, 
theophyllin etc.) 
ANTIBIOTICS : Antibiotics are very important class of 
phrmaceuticals consisting of antibacterials, anti 
infectives, antifungals, antiparasitics and 
antimicrobials. Antibiotics are organic compounds in 
their chemical nature. Antibiotics are chemical 
compounds derived from or produced by living 
organisms, which are capable, in small concentraions, 
of inhibiting the life processes of microorganism. (2). 
The chemistry of antibiotics is so varied 
that a chemical classification is of little value. 
However, some antibiotics are the products of 
similar mechanisms in different organisms and that 
these structurally similar products may exert their 
activities in a similar manner. A number of 
antibiotics have in common a macrolide structure, 
that is, a large lactone ring. Erythromycin, 
oleandomycin are included in this family. Tetracyclin 
family represents a group of compounds very closely 
related chemically. Streptomycins, Kanamycins, 
neomycins, paramomycins and gentamycins are included 
into a family of compounds containing closely related 
amino sugar moities. The antifungal antibiotics 
nystatins and amphotericins are examples of a group 
of conjugated polyenes. The pencillins and cephalo 
sporins are antibiotics derived from amino acids. A 
large number of polypetide compounds that exhibit 
antibiotic action include bacitracins, tyrothricins 
and polymixins. 
ANALGESICS : A drug which brings about insensibility to 
pain without loss of consiousness is known as analgesic. 
There are numerous drugs which , in addition to 
possessing distinctive pharmacologic activities in other 
area, may also posses analgetic properties (3). The 
analgetic property may have direct or indirect effect. 
Such class of drugs are grouped as sedatives (eg. 
barbutrates); muscle relaxents (eg, mephenesin, 
methocarbamol); tranquilizers (eg. meprobamate); 
morphine and related compounds (morphine, hydromorphine 
and codeine phosphate/sulphate etc); synthetic 
analgesics (pentazocaine, methotrimeprazine, methadone 
hydrochloride, nefopam etc. ) ; antipyretic analgesics ( 
salicylic acid derivatives, arylacetic acid 
derivatives, aniline and p-aminophenol derivatives, 
pyrazolone and pyrazolidinedione derivatives). 
CENTRAL NERVOUS SYSTEM DEPRESSANTS : The agents 
that produces depressent effect on the central 
nervous system (U) as their principle pharmacological 
action, include the general anesthetics, hypnotic 
sedatives, skeletal muscle relaxents, tranguilizing 
agents and anticonvulsants. The general anesthetics 
(eg. ether) and hypnotic sedatives (eg. phenobarbital) 
produce generalized or non-selective depression on 
C.N.5. function. Many sedatives if given in large doses, 
produce anesthesia. Certain. analgesics also produce 
depression on central nervous system. 
CENTRAL NERVOUS SYTEM STIMULANTS : Central nervous 
system is a complex network of subunits which act as 
conducting path ways between peripheral receptors and 
effectors, enabling man to respond to his environment. 
Drugs which have in common the property of 
increasing the activities of various portions of the 
central nervous system are called (5,6) central 
nervous system stimulants (respiratory stimulants and 
analeptics). Carbonic acid is a most effective 
respiratory stimulant. 
Analeptics, agents used to lessen narcosis 
brought about by excess of depressant drugs often stimulate 
a variety of nerve centres as well as many analeptic 
drugs are also pressor durgs because their 
stimulation of the vasomoter centre produce an increase 
in vasoconstriction. 
There are many drugs (cocaine, atropine, 
amphetamines, ephidrine etc.) of varying pharmacologic 
classes,in addition to, their desired effect elicit a 
pronouneed stimulatory effect on central nervous 
sytem. 
CARDIOVASCULAR AGENTS : Agent used for their action 
on the heart or on other parts of the vascular system so 
that they modify the total output of the heart or the 
distribution of blood to certain parts of the 
circulatary system, are called cardiovascular agents 
(7), This class include cardiotonic drugs vasodialators, 
hypotensive drugs, antihyper cholesterolemic drugs and 
sclerosing agents (8). Certain drugs have a direct 
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action on cardiovascular sytem, and in addition, this 
calss of drug that affect certain constituents of blood. 
The later include anticoagulant drugs, the hypoglycemic 
agents the thyroid harmones and the antithyriod drugs. 
In this dissertation we have developed a new 
method for the determination of thyroxine sodium in drug 
formulations, therefore,a more detailed study has been 
done on the drug. 
Thyroxine (9) is an active substance which is 
isolated from thyriod gland (usually the sheep). It 
is the tetra - iod - derivatives of amino acid. 
^__>-CH2CH(NH2)COOH 
V r 
THROXINE SODIUM 
Thyroxine sodium is a c rude s a l t . It has the 
several thousand times the activity of a fresh gland. 
Def fated thyroid s u b s t a n c e has been used for many 
years as a replacement theraphy in thyriod gland 
defficiencies (10-12). The efficancy of the t h y r o i d 
gland is known to depend on its thyroglobulin content 
which is an i o d i n e containing globulin. Kendall in 
1916 obtained thyroxine as a crystalline derivative and 
found t h a t i t showed as such the same a c t i o n as the 
whole thyroid substance. Recent studies show that even 
more potent iodine containing harmone exist, which is 
known as trii odothyronine. Thyroxine is supposed to be 
the storage form of the harmone, while the triodothy-
ronine is the circulatory form. In the blood 
thyroxine is more firmly bound to the globulin 
fraction than is triodothyronine, which can then enter 
the tissue cells. 
LEVOTHYROXINE SODIUM U.S.P. : sodium L-3-[4-(4-hydroxy-
3, 5 diodophenoxy) -3, 5-diodophenyl] alanine, sodium 
L-3-, 3, 5 5, -tetraiodothyronine. This compound is the 
sodium salt of levosomer of thyroxine, which is an 
active physiological principle obtained from the 
thyriod gland of domesticated animals use for food by 
man. It is also prepared synthetically. The salt is 
light yellow tasteless odourless powder. It Is 
hygroscopic but stable in dry air at room -iemperature. 
It is soluble in alkali hydroxides, 1:275 in alcohol 
and 1:500 in water to give a pH of ^^ 8.9. 
m 
CH2-CHC00-Na 
LEVOTHYROXINE SODIUM 
Levothyroxine sodium i s used in r ep lacemen t t h e r a p y of 
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deceased thyroid function (hypothyroidism). In general, 
lOOJU^g of levo thyroxine sodium is clinically equivalent 
to thyroxine 30-60 mg of thyroid U.S.P. 
LIOTHYRONINE SODIUM U.S.P. CYTOMEL Sodium L-3 [A~( 
4- hydroxy -3-iodophenoxy) -3,5-diodophenyl ] alanine is 
the sodium salt of L-3,3,5, triiodo thyronine. It 
occurs as a light tan, odourless, crystalline powder 
slighitly soluble in water or alcohol and has a 
specific rotation of +18° to +22° in acid (HCl) 
alcohol. 
- + H2CHNH2-COO.Na 
LIOTHYRONINE SODIUM 
Liothyronine occurs in vivo together with levothyroxin e 
it has the some qualitative activities as thyroxine 
but is more active. It is absorbed readily from the 
gastrointestinal tract, is cleared rapidly from the 
blood stream and is bound more closely to the plasma 
proteins than the thyroxine, propbably due to the less 
acidic phenolic hydroxyl group. 
It is used same as that of levothyroxine, 
including treatment of matsbolic in sufficiency, male 
infertility and certain avmcoloaical disorder. 
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ANALYSIS OF DRUG : The methods for analyzing medicinal 
agents are divided into physical, chemical, physico-chemical 
and biological once. 
Physical methods of analysis involve the studying 
of the physical properties of a substance. They include 
the determination of solubility transparency and the 
degree of turbidity, colour, density or specific 
gravity, metting, boiling and freezing points. 
Chemical method used for the analysis of durgs 
are based on chemical reactions. They include the 
determination of ash content, the hydrogen ion 
concentration (pH) of medium and characterstic numerical 
indices of oils and fats. Quantitative and qualitative 
analysis of durge are generally carried out with 
respect to functional groups. 
Physcochemical methods are used to study the 
physical phenomenon that occur as a result of chemical 
reaction. Among the physiocochemical method of analysis, 
photometry including photocolorimetry and 
spectrophotometry, electrochemical and chromatographic 
methods. Recently various kinds of chromatography 
(column, paper, thin layer, gas, gas-liquid) and of 
photometric methods based on the absorption of light by 
the analyte have found there use in pharmaceutical 
analysis. NMR, PMR, and mass spectrometry with gas chromatography 
12 
are the most important powerful analytical methods 
used for the analysis of drug. 
Biological method of anlaysis characterizes 
the pharmaceu tical effect of the drug. Biological 
tests are conducted on animals and less frequently 
separate isolated organs or part of organs of animals. 
The effect of durg is expressed in A.U. (activity units) 
and is determined by the comparision with the activity 
of a reference substance. The biogical methods are very 
sensitive. Alkalo ids, vitamins and antibiotics, still 
reveal activity when diluted millions of times. 
Photocolorimetric methods of analysis are 
based on measuring the absorption of non-monochromatic 
light by coloured compounds, in the visible part of 
the spectrum. If the analytes are colourless, they are 
converted into coloured compounds by reaction with 
suitable reagent. In the visual method, called 
colorimetry, the intensity of the colour of analyte 
solutions is compared to that of standard solutions 
if the concentration of substance is known. 
In the recent years, pharmacentical analysis has 
been chracterized by the use of methods such as flame 
photometry and diffrential spectrophotometry in the 
qualitative analysis of drugs. These methods enable 
one to determine the large amount of individual 
components of a mixture because the absorbance of the 
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analyte solution is measured not rela.tive to the 
pure solvent (or a solution of reagent), but relative 
to a reference solution containing a known amount of 
the analyte. 
For the determination of specific pencillin in 
pharmaceutical products spectrophotometric methods have 
been developed. Spectrophotometry has been used for 
the determination of amoxycillin (13, lU, 15). 
Chromatograhic procedure have appeared for ampicillin, 
amoxycillin and pencillin G (16). A diazotization 
spectrophotometric method has been used to chracterize 
amoxycillin by reaction with aromatic amines and 
amino acids in bulk drugs and also in capsules, 
tablets and syrups. A polymer immoblized enzyme 
optrode for pencillin has been introdused for 
determination of pencillin (17). 
H' NMR has been applied most frequently to 
the analysis of common analgesices (18,19) B- androgenic 
blockers (20), and the antineoplastic ziechlorethamine 
hydro chloride (21) and carbachol (22). Near IR 
analysis has been used to assay tablets containing 
acetaminophen in combination with caffeine (23). The 
procedure was adopted to cough cold syrups. Sulpuar 
based cardiovascular drugs, antiallergy or anti 
inflammatory durgs and phenothizine have been 
analyzed by 'H^ and C NMR spectroscopy (2^, 25). 
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A variety of cololimetric procedures have been 
developed for analgesics, antipyretics and 
antiinflammatories. Acetaminophen has been measured by 
itself (26, 27) and in conbination with other compounds 
such as salicylamide and oxyphenbutazone (28, 29). 
Methods have also ben published for aspirin (30, 31) 
Novalgin (32, 33) dipyrone (3U), indomethacin (35), 
naproxen (36), and oxypheubutazone (37). 
Iron reagents have been used to assay the 
chlorpheniramine and pheniramine (38), meperidine 
(39), nifedipine (40), nitrazepam (41), and nitroxazephine 
HCl (42). A simple and sensitive ion-exchange method 
has also been published for the detection of 
chlorpromazine in human urine (43). Other types of 
colorimetric procedures have also been developed for 
the analysis of pharmaceuticals. Oureshi and 
co-workers have recently developed. s pectrophotometric 
methods for the determination of paracetomol (44^ and 
acetaminophen (45) . 
During the last 5 years a variety of 
electroanalytic, chromatographic and spectroscopic assay 
have appeared for the selective determination of 
vitamin C. Spectroscopic methods are based on the 
oxidation of ascorbic acid. A method based on 
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inhibition of peroxides activity has been described 
(46). An extraction spectrophotometric procedure have 
also been developed for the determination of vitamin C 
(1*7) in drug formulations, urine and fruit guices with 
potassium iodate. 
Calorimetric procedures have been found based on 
either the formation of charge transfer complex 
between the active and iodine (48, 49), nitrosation of 
active (50, 51) or reaction of or, active with a 
diazotized reagent (52, 53). Recently a review on the 
analysis of pharmaceuticals and related drugs have 
been appared (54), representing a survey of 
pharmaceutical analysis and related methodology. 
The determination of iodin^ted thyronines is 
of great importance. As the concentration of iodinated 
thyronines in plasma are very low; only trace method 
can be applied for the determination. Radioimmunoassay 
(54, 55), fluorescence immunoassay (57), enzyme 
immunoassay (58) and competitive protein bin-ding assay 
(59), are most frequently used for the determination 
of thyroxine sodium. A selective determination of 
enatiometric thyromines is not possible with these 
techniques. The reaction of L-thyroxine antibodies 
with D-tbyroxine for a radioommunoassay was found to 
be 100^ (60). 
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Recently the determination of D.L-triiodothyronine 
and D.L-thyroxine by derivatization liquid chromatography 
has been described (61). The D.L-thyronines are 
derivatized with tertiarybutyloxy -L- leucine -N- hydroxy 
succinimide ester and the resulting diasteromeric peptides 
are separated by ion pair chromatorgraphy on reveresed 
phase columns. This method was successfully applied to 
the control of purity of pharmaceuticals and its 
applications in human plasma seemed to be promising. 
Chromatographic separations of thyroid barmons can be 
carried out using gel chromatography (62, 63), 
ion-exchange chromatography (6^, 65), gas chromatography 
(6U), high performance liquid chroomatography HPLC (65). 
Van der shiji and I, verms et al (66) have 
reported the effect of temperature on free thyroxine 
measurements and its analytical, and clinal consequences. 
Throxine and 3,5,3, - triiodoothyroxine has been 
determined by sub and super equivalance isotope dilution 
analysis (67) at trace level (160 and 20 mg/ml) and 
radioimmunoassay (68), for measurement of free 
thyroxine in serum. New homogenious enzyme immunoassay 
for the determination of theyroxine and thyroxine uptake 
have been developed recently (69). A multicentre evaluation 
of a two step enzyme immunoassay (70) of free thyroxine 
have also been developed. 
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In this dissertation, we describe the 
determination of thyroxine sodium in pure and dosage 
forms using well known diazotization reaction. The 
method is based on the reaction of amino group with 
nitrous acid in an ice-cold medium. 
18 
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SPECTROPHOTOMETRIC DETERMINATION 
OF 
THYROXINE SODIUM 
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INTRODUCTION 
The human thyroid gland produces L-isomers 
of thyroxine sodium and D-isomer is being produced 
synthetically. D-thyroxine has been found to reduce 
the cholestrol level significantly, by increasing the 
rate of degradation and oxidation of cholestrol (1-4). 
D-thyroxine has been described to cause the supression 
of thyrotropine. 
Levothyroxine sodium i.e. thyroxine sodium 
(L-3-3', 5-5'-tetraiodothyronine), which is an active 
physiologic principle obtained from the thyroid gland of 
domesticated animals used for food by man (5). It is- used 
in replacement therapy of decreased thyroxine function 
(hypothyroidism). 
The British pharmacopoeia 1980 estimated (6) 
thyroxine sodium by applying the oxygen-flask combustion 
for iodine. Several other analytical procedures have 
been reported for the determination of thyroxine 
sodium, include polarography (7), gas chromatography 
(8,9), thin layer chromatography (10,6) and high 
performance liquid chromatography (11, 12) and isotope 
dilution analysis (13). Radioimmunoassay (14, 15 , 16), 
enzyme immunoassay (17,18), colourimetrie (19) and 
fluorometric (20) procedure for the determination of 
thyroxine sodium have also been developed. An 
spectrophotometric method (21) for the determination of 
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thyroxine sodium with p-benzoquinone have been 
appeared recently. 
In this investigation a spectropbotometric 
method for the determination of thyroxine sodium based 
on the reaction of nitrous acid with functional group 
of thyroxine sodium, in an ice-cold medium (0-5°C) 
has been described. 
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EXPERIMENTAL 
Reagents and Apparatus : A 1 mg/ml solution of 
thyroxine sodium (Glaxo India) was prepared in a 
alcohol-dimethyl sulphoxide mixture (50:50, v/v) . A 0.2 
M sodium nitrite (freshly prepared daily) and 1.5 M 
hydrochloric acid solutions were prepared in high 
purity conductivity water. All other chemicals used 
were of analytical grade. 
A Bausch & Lomb 5pectronic-20 spectrophotometer 
was used for absorptiometric measurements. 
Procedure : To a precooled solutions of 3.5 ml sodium 
nitrite and 1.5 ml HCl in a 10 ml volumetric flasks, 
added accurately measured volume of thyroxine sodium 
(0.1-1,6 ml) and mixture was then diluted upto the mark 
with 50:50 alcohol : DMSO mixture (v/v). The flask were 
then kept for 15 minutes in ice-cold bath for the 
complete development of yellow colour and absorbances were 
read at 410 nm against a reagent blank. Calibration 
graph is shown in figure. 3 
RESULTS AND DISCUSSION 
Nitrous acid has been proved to be useful 
reagent for the determination of amines and amino acids. 
The reaction is carried out by adding aqueous solution of 
sodium nitrite to a cold aqueous solution of amine or 
amino acids in dilute mineral acids (22). 
Thyroxine sodium with structural formula 
sodium-L-3 l^-(U-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenly] 
alanine, or sodium L-3, 3', 5,5'-tertraiodothyroxine is the 
levoisomer of thyroxine. 
LEVOTHYROXINE SODIUM 
The reaction of thyroxine sodium with nitrous 
acid involves the possible kinetic mechanism of the 
following functional groups. 
1. Involvement of aliphatic primary amine -NH^ group. 
2. Carboxylic group 
3. Hydroxy group 
4. Iodide group 
In the above groups the most effective activation 
involves the action of nitrous acid on -NH- group. The 
rest of the groups do not have the condusive conditions to 
be activated. We therefore decided to discuss a tentative 
mechanism of aliphatic primary amines with nitrous acid. 
However, the product formed is extremely unstable and there-
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fore the possibility of such reaction is ruled out. In 
another approach the formation of nitrosamine which is 
characteristically pale yellow appears to be more positive. 
Although it is also unstable but the possibility of making 
it stable under experimentalconditions can not be ruled out. 
The reaction is quantitative one, involving the 
measurement of intensity of yellow colour using alcohol : 
DM50 (1:1); DMSO has a boosting effect on increasing colour 
intensity. The effect of solvent on equilibrium constant 
(K), the heat of formation, and the molar extinction 
coefficient ( X ^ ^^s been studied on the formation of 
•complexes of nitro compounds. Dimethylsuplphoxide plays 
an important role to enhance the colour intensity (23) of 
these compounds and the most versatile example of the use 
of DMSO, is the detection of nitro compounds, where the 
sensitivity of the identification is increased 
tremendously (24). 
Nitrous acid is unstable and is usually prepared 
by mixing a freshly prepared solution of NaNo (sodium 
nitrite) with appropriate concentration of hydrochloric 
o 
acid at 0^5C . These conditions provide a source of NO 
which is transferred readily to the nucleophilic nitrogen 
of amine. _ ^^ 
HONO -h He " Hp + : N = 0 
— N : + : N = 0 » -(Ji^=^N=0 
In ' the reaction of primary aliphatic aaine 
present in throxine sodium, formation of N-nitrosaaine 
takes place as follows. 
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STUDY OF THE PROPOSED EXPERIMENTAL CONDITIONS 
Under the proposed experimental conditions 0.6 
ml of 1.5 M HCl and 2.0 ml of 0.2M sodium nitrite (Table 1 
and 2) was found sufficient to produce high intensity 
coloured product for 0.5 ml of drug. The results are 
shown in Fig. 2 and 3. Beer's law is obeyed in the 
concentration range of 10 ug/mt- 160 ug/ml of thyroxine 
3 
sodium with apparent molar absorptivity of 3.56 x 10 Z 
-1 -1 
mol cm 
To test the reproducibility of the procedure 10 
replicate determinations of 0.5 ml and 1.0 ml thyroxine 
sodium were done. The relative standard deviation was 
found to be 0. 65h and 0.85% for 0.5 ml and 1.0 ml of 
thyroxine sodium respectively. Statistical analysis (Table 
3) of the result obtained by proposed method and by other 
spectrophotometric method (21) showed no significant 
difference between the performance of the two methods. 
Interferences of various ingradients used for 
the preparation of thyroxine sodium tables were checked. 
The results are shown in table 4 and no interference was 
found for these ingradients. 
The work is under progress and its application 
for the analysis of conmercial thyroxine sodium tablets is 
under study. 
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TABLE 1. Effect of varying volume of HCl on the formation of 
thyroxine sodium complex. 
Amount of Amount of Amount of Absorbance at 
Drug taken HCl (1.5 M) NaNO^ (0.2M) 410 nm 
(ml) (ml) ?ml) 
0.5 0.2 3.5 0.10 
0.5 0.4 3.5 0.18 
0.5 0.6 3.5 0.26 
0.6 0.8 3.5 0.27 
0.5 1.0 3.5 0.27 
0.5 1.2 3.5 0.27 
0.5 1.4 3.5 0.27 
0.5 1.5 3.5 0.27 
Temperature ice cold bath (0-5°C). 
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TABLE 2. Effect of varying volume of NaNO on the formation 
of thyroxine sodium complex. 
Amount of Amount of Amount of Absorbance at 
drug taken NaNO (0.2M) HCl (1.5M) 410 nm 
("^^ (ml) (ml) 
0.5 0.5 1.5 0.22 
0.5 1.0 1.5 0.24 
0.5 1.5 1.5 0.26 
0.5 2.0 1.5 0.27 
0.5 2.5 1.5 0.27 
0.5 3.0 1.5 0.27 
0.5 3.5 1.5 0.27 
Temperature - ice cold bath (0-5°C). 
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TABLE 3. Statistical analysis of proposed method and other 
spectrophotometric method. 
Method Beer's law obeyed apparent molar Relati^B S.D. 
in cone, range absorptivity 
3 
Proposed 10 - 160 ug/ml 3.56x10 +_0.65', 
,--i -1 1 mol cm 
3 
Reference 40 - 200 ug/ml 2.9x10 +_0.36' 
(21) 1 mol'-^cm'''' 
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TABLE 4. Interferences of foreign substances for the 
estimation of thyroxine sodium (50 ug/ml) 
S.NO. Foreign Substance Maximum tolerable amount 
(mg) 
32.1*28 
36.432 
72.464 
68.46 
8.01 
12.0 
32.48 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Glucose 
Fructose 
Lactose 
Sucrose 
Ca'^ 
''3 
Starch 
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